Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2022-01-26
- Target Recruit Count
- 118
- Registration Number
- NCT03837873
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳the First Affiliated Hospital of Jilin University, Changchun, Jilin, China
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University of Turin, Italy
- Target Recruit Count
- 450
- Registration Number
- NCT03829371
- Locations
- 🇮🇹
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Torino, TO, Italy
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Landspitali University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03815279
- Locations
- 🇮🇸
Landspitali University Hospital, Reykjavík, Iceland
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone
- Conditions
- Interventions
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Kosin University Gospel Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT03809780
- Locations
- 🇰🇷
Kosin University Gospel Hospital, Busan, Western, Korea, Republic of
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03785184
- Locations
- 🇦🇺
St. Vincents Hosp Melbourne /ID# 210266, Fitzroy, Victoria, Australia
🇨🇦Hopital Maisonneuver-Rosemont /ID# 208550, Montreal, Quebec, Canada
🇦🇺Austin Hospital /ID# 210268, Heidelberg, Victoria, Australia
CURATE.AI Optimized Modulation for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 20
- Registration Number
- NCT03759093
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT03746223
- Locations
- 🇨🇳
Peking Union medical college hospital, Beijing, Beijing, China
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT03733691
- Locations
- 🇺🇸
James R Berenson, MD, Inc., West Hollywood, California, United States
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
- Conditions
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 250
- Registration Number
- NCT03729804
- Locations
- 🇺🇸
University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 690
- Registration Number
- NCT03710603
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Australia
🇩🇰Odense University Hospital, Odense, Denmark
🇫🇷CHRU Hôtel Dieu, Nantes, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.